[ET Net News Agency, 10 July 2026] Morgan Stanley lowered the target price for Fosun Pharma (02196) to HKD28.5 from HKD32 and maintained the "overweight" rating.
The research house said 2027/28 EPS forecasts decrease by 5%/11%, respectively. (rc)
The research house said 2027/28 EPS forecasts decrease by 5%/11%, respectively. (rc)